 Chronic myeloid leukaemia (CML) is characterized by the Philadelphia chromosome resulting in the BCR-ABL1 gene whose mRNA transcript detection is commonly used for diagnosis and monitoring of therapeutic response.     ///    Patient-specific individual BCR-ABL1 fusion sites were successfully detected in 10 out of 13 patients.     ///    Identification of the genomic BCR-ABL1 fusion sequence from blood specimen stored on filter paper..     ///    DNA was isolated from dried blood stains from CML patients stored on filter paper (Guthrie cards) after a median period from diagnosis of 11 years (range: 5-12 years) and analyzed with a two round long-range multiplex PCR (MLR-PCR) to identify the genomic BCR-ABL1 breakpoint. 